Registered title, quoted from ClinicalTrials.gov
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
An open trial on lung cancer and breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 15 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 15
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
- Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
- Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
- Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
- Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
- Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
- Study siteMeizhou People's Hospital梅州市人民医院MeizhouHospital page
- Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
- Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
- Study siteXiangyang Central Hospital襄阳市中心医院XiangyangHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07169994, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs).
Exclusion criterion 1
Patients who have received major surgery (excluding diagnostic surgery) within 4 weeks before the first dose of the investigational product or those who are expected to receive major surgery during the study.
Exclusion criterion 5
Prior treatment with systemic steroids (prednisone > 10 mg/day or equivalent) or other immunosuppressive treatment within 2 weeks before the first dose of the investigational product.
Exclusion criterion 7
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
Inclusion criterion 4
Have at least 1 extracranial measurable tumor lesion.
Inclusion criterion 7
With known human immunodeficiency virus (HIV) infection.
Exclusion criterion 17
With active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Exclusion criterion 18
With a medical history of any other primary malignancies within 5 years before the first dose of the investigational product.
Exclusion criterion 19
Lactating women, or women who are confirmed pregnant via a pregnancy test within 3 days before the first dose.
Exclusion criterion 22
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07169994, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Informed of the study before the start of the study and voluntarily sign their name and date in the informed consent form (ICF)
- Able and willing to comply with protocol visits and procedures
- Aged between 18 to 75 years
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Previously treated by standard treatment or have not been treated for metastatic setting;
- Adequate organ and bone marrow function.
- Have at least 1 extracranial measurable tumor lesion.
- Adequate archival formalin-fixed paraffin embedded (FFPE) tissue from prior biopsy.
Exclusion Criteria:
- With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs).
- Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors.
- Are participating in another clinical study, unless it is an observational (non-interventional) clinical study or in the follow-up period of an interventional study.
- The washout period from the previous anti-tumor therapy is insufficient before the first dose of the investigational product.
- Patients who have received major surgery (excluding diagnostic surgery) within 4 weeks before the first dose of the investigational product or those who are expected to receive major surgery during the study.
- Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation.
- Prior treatment with systemic steroids (prednisone > 10 mg/day or equivalent) or other immunosuppressive treatment within 2 weeks before the first dose of the investigational product.
- Patients who have received any live vaccine within 4 weeks before the first dose of the investigational product or those who plan to receive live vaccine during the study period.
- With meningeal metastasis or cancerous meningitis.
- With brain metastasis or spinal cord compression.
- Patients with uncontrolled or clinically significant cardiovascular diseases.
- Clinically significant complicated pulmonary disorders.
- Patients diagnosed with Gilbert syndrome.
- Those with uncontrolled effusion in the third space requiring repeated drainage.
- With a medical history of gastrointestinal perforation and/or fistula within 6 months before the first dose, or with active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases that may lead to hemorrhage or perforation according to the investigator.
- With serious infection before the first dose.
- With known human immunodeficiency virus (HIV) infection.
- With active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- With a medical history of any other primary malignancies within 5 years before the first dose of the investigational product.
- Unrelieved toxicity of previous anti-tumor therapy.
- With a history of severe hypersensitivity to inactive ingredients in the raw materials and drug product or other monoclonal antibodies.
- Lactating women, or women who are confirmed pregnant via a pregnancy test within 3 days before the first dose.
- With any diseases, medical conditions, organ system dysfunction, or social conditions that may interfere with the ability of subjects to sign the ICF, adversely affect the ability of subjects to cooperate and participate in the study, or affect the interpretation of study results, including but not limited to mental illness or substance/alcohol abuse, in the opinion of the investigator.
Quoted from ClinicalTrials.gov, NCT07169994, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07169994, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.